doi:10.1097/HC9.0000000 000000488 Fichez J, Mouillot T, Vonghia L, et al
Although these studies demonstrated how GLP-1 agonists can worsen diabetic gastroparesis and specifically advised against using GLP-1 agonist therapy in people with similar symptoms, Novo Nordisk failed to inform doctors about this potential issue and did not alter their prescribing or dosage recommendations
Take body measurements of your waist, hips, arms, and thighs to see how your body changes
Ideally, complete your full semaglutide titration to maximum tolerated dose before making this decision
Mechanisms of migraine as a chronic evolutive condition
Attempts at cost-effectiveness evaluations have been made, but progress has been slow